Synopsis

Conclusions
Bimekizumab demonstrated greater skin clearance that 
was durable in patients with moderate to severe plaque 
psoriasis as compared with ustekinumab, regardless of 
patient subgroup.

These results support bimekizumab as a psoriasis treatment 
suitable for a wide variety of patients given its consistent 
efficacy across all subgroups analyzed.

Objective
To assess the efficacy of bimekizumab compared 
with ustekinumab over 52 weeks of treatment across 
demographic, disease characteristic, and prior treatment 
history subgroups of patients with moderate to severe 
plaque psoriasis from the BE VIVID study.

Background
• Bimekizumab is a monoclonal IgG1 antibody that 

selectively inhibits IL-17F in addition to IL-17A, both 
of which play a pivotal role in the pathogenesis of 
psoriasis (PSO).1–4 

• Given that the severity of PSO can vary with age, 
weight and prior treatment exposure,5 there is a need 
for therapies that provide consistent and durable skin 
clearance, regardless of patient/disease characteristics 
and treatment history.

Methods
• In BE VIVID (NCT03370133), patients were randomized 

to receive bimekizumab through Week 52, ustekinumab 
through Week 52, or placebo to Week 16 followed by 
bimekizumab (patients randomized to placebo were not 
included in these analyses; Figure 1). 

• Subgroup analyses were conducted based on patient 
demographics, disease characteristics, and prior 
treatment exposure.

• Proportions of bimekizumab- versus ustekinumab-treated 
patients achieving 90% and 100% improvement from 
baseline Psoriasis Area and Severity Index (PASI 90 and 
PASI 100) were calculated at Weeks 16 and 52. Missing 
data were imputed as non-response (NRI).

Results
Patient Population

• Baseline characteristics for patients randomized to 
bimekizumab or ustekinumab are shown in Table 1.

Bimekizumab Efficacy Across Subgroups

• PASI 90 (Figure 2) and PASI 100 (Figure 3) response rates 
were greater in patients randomized to bimekizumab 
compared with ustekinumab across all subgroups 
at Week 16.

• Responses were further improved or maintained in 
bimekizumab-treated patients through Week 52 and 
remained higher than responses in patients receiving 
ustekinumab (Figure 2 and Figure 3).

B. Strober,1,2 J.G. Krueger,3 N. Magnolo,4 R. Vender,5 D.P. Toth,6  
D. Thaçi,7 M. Wang,8 C. Cioffi,8 C. Madden,8 R.B. Warren9

BSA: body surface area; DLQI: Dermatology Life Quality Index; IGA: Investigator’s Global Assessment; IL: interleukin; IMP: investigational medicinal product; ITT: intention-to-treat; NRI: non-responder imputation; PASI: Psoriasis Area and Severity Index; Q4W: every 4 weeks; Q12W: every 12 weeks; SD: standard deviation; TNF: tumor necrosis factor.

Figure 1 Study design

Bimekizumab 320 mg  
Q4W (n=321)

Ustekinumab 45/90 mg 
Q12Wb (n=163)

Age (years), mean ± SD 45.2 ± 14.0 46.0 ± 13.6

<40 years, n (%) 123 (38.3) 57 (35.0)

40–<65 years, n (%) 164 (51.1) 88 (54.0)

≥65 years, n (%) 34 (10.6) 18 (11.0)

Male, n (%) 229 (71.3) 117 (71.8)

Caucasian, n (%) 237 (73.8) 120 (73.6)

Weight (kg), mean ± SD 88.7 ± 23.1 87.2 ± 21.1

≤100 kg, n (%) 226 (70.4) 122 (74.8)

>100 kg, n (%) 95 (29.6) 41 (25.2)

Duration of psoriasis (years),  
mean ± SD

16.0 ± 11.6 17.8 ± 11.6

<Median (14.54 years), n (%) 169 (52.6) 73 (44.8)

≥Median (14.54 years), n (%) 152 (47.4) 90 (55.2)

PASI, mean ± SD 22.0 ± 8.6 21.3 ± 8.3

PASI<20, n (%) 170 (53.0) 102 (62.6)

PASI≥20, n (%) 151 (47.0) 60 (36.8)

BSA (%), mean ± SD 29.0 ± 17.1 27.3 ± 16.7

IGAc, n (%)

3: moderate 201 (62.6) 96 (58.9)

4: severe 119 (37.1) 66 (40.5)

DLQI total, mean ± SD 9.9 ± 6.3 11.0 ± 6.9

Prior biologic therapy, n (%) 125 (38.9) 63 (38.7)

anti-TNF 51 (15.9) 24 (14.7)

anti-IL-17 76 (23.7) 38 (23.3)

anti-IL-23 16 (5.0) 6 (3.7)

Institutions: 1Yale University, New Haven, CT, USA; 2Central Connecticut Dermatology Research, Cromwell, CT, USA; 3The Rockefeller University, New York, NY, USA; 4Universitätsklinikum Münster, Münster, Germany; 5McMaster University, Hamilton, ON, Canada; 6Probity Medical Research; Windsor, ON, Canada; 7Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany; 8UCB Pharma, Raleigh, NC, USA; 9Dermatology Centre, 
Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK.

Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients 
with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, 
Randomized, Double-Blinded Phase 3 BE VIVID Trial

Presented at Winter Clinical 2021 Virtual Congress  |  January 16–24

References: 1Durham L. Curr Rheumatol Reports 2015;17:55; 2Fujishima S. Arch Dermatol Res 2010;302:499–505; 3Glatt S. Br J Clin Pharmacol 2017;83:991–1001; 4Papp KA. J Am Acad Dermatol 2018;79:277–86.e10; 5Kamiya K. Int J Mol Sci 2019;20:4347. Author Contributions: Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: BS, JGK, NM, RV, DPT, DT, MW, CC, CM, RBW; drafting of the publication, or revising it critically for important 
intellectual content: BS, JGK, NM, RV, DPT, DT, MW, CC, CM, RBW; final approval of the publication: BS, JGK, NM, RV, DPT, DT, MW, CC, CM, RBW. Author Disclosures: BS: Consultant (honoraria) from AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, Equillium, GSK, Janssen, LEO Pharma, Meiji Seika Pharma, Mindera, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma and 
UCB Pharma; speaker for AbbVie, Amgen, Eli Lilly, Janssen and Ortho Dermatologics; Scientific Director (consulting fee) for Corrona Psoriasis Registry; Investigator for AbbVie, Cara, Corrona Psoriasis Registry, Dermavant, Dermira and Novartis; Editor-in-Chief (honorarium) for Journal of Psoriasis and Psoriatic Arthritis; JGK: Grants paid to institution from AbbVie, Akros, Allergan, Amgen, Avillion, Biogen MA, Boehringer Ingelheim, Botanix, Bristol Myers Squibb, Celgene, Eli Lilly, Exicure, 
Incyte, Innovaderm, Janssen, LEO Pharma, Novan, Novartis, Paraxel, Pfizer, Regeneron, Sienna, UCB Pharma and Vitae; personal fees from AbbVie, Allergan, Almirall, Amgen, Arena, Aristea, Asana, Aurigne, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Escalier, LEO Pharma, Nimbus, Novartis, Menlo, Pfizer, Sanofi, Sienna, Sun Pharma, UCB Pharma and Valeant; NM: Honoraria, advisor, and/or paid speaker for and/or participated as principal investigator in clinical 
trials for AbbVie, Almirall, Asana, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Dermira, Dr. Reddy’s Laboratories, Eli Lilly, Galderma, Genentech, Incyte, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sun Pharma and UCB Pharma; RV: Consultant, and/or scientific advisor, and/or investigator, and/or speaker for AbbVie, Amgen, Astellas, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermira, Eli Lilly, 
Galderma, GSK, Janssen, LEO Pharma, Merck (MSD), Merck Serono, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda and UCB Pharma; DPT: Investigator and/or speaker for AbbVie, Amgen, Arcutis, Avillion, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, GSK, Incyte, Janssen, LEO Pharma, Merck-Serono, Novartis, Pfizer, Regeneron, Sanofi-Aventis/Genzyme, Sun Pharma and UCB Pharma; DT: Honoraria 
for participation on advisory boards, as a speaker and for consultancy from AbbVie, Almirall, Amgen, Biogen-Idec, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DS-Biopharma, Eli Lilly, Galapagos, Janssen, LEO Pharma, Morphosis, Novartis, Pfizer, Regeneron, Samsung, Sandoz-Hexal, Sanofi and UCB Pharma; Research grants received from Celgene and Novartis; MW: Employee of UCB Pharma; CC, CM: Employees and shareholders of UCB Pharma; RBW: Research grants from 
AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer and UCB Pharma; Consultant for AbbVie, Almirall, Amgen, Arena, Avillion, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB Pharma. Acknowledgements: This study was funded by UCB Pharma. We would like to thank the patients and their caregivers in addition to all the investigators and their teams who contributed to this study. The authors 
acknowledge Mylene Serna, PharmD, UCB Pharma, Smyrna, GA, USA and Susanne Wiegratz, MSc, UCB Pharma, Monheim am Rhein, Germany for publication coordination; Eva Cullen, PhD, UCB Pharma, Brussels, Belgium for critical review; Kristian Clausen, MPH, Costello Medical, Cambridge, UK for medical writing and editorial assistance; and the Costello Medical Design Team for design support. All costs associated with development of this presentation were funded by UCB Pharma.

Previously presented at EADV 2020 Virtual Congress  |  October 29–31

aRandomization was stratified by prior biologic exposure and region; bPatients randomized to placebo were not included in 
these analyses; cUstekinumab dosing was based on weight: patients ≤100 kg at baseline received one ustekinumab 45 mg 
injection and one placebo injection; patients >100 kg at baseline received two ustekinumab 45 mg injections (90 mg total).

Table 1 Baseline characteristicsa

aPatients randomized to placebo are not shown here; bUstekinumab dosing was based on weight: patients  
≤100 kg at baseline received one ustekinumab 45 mg injection and one placebo injection, patients >100 kg at 
baseline received two ustekinumab 45 mg injections (90 mg total); cIn each treatment group, one patient with 
IGA=2 was mistakenly enrolled. 

Figure 2 Achievement of PASI 90 at Weeks 16 and 52 (ITT, NRI)

A) Week 16

Bimekizumab demonstrated greater skin clearance vs 
ustekinumab, regardless of patient subgroup.

Bimekizumab vs

Subgroup Analyses:

Figure 3 Achievement of PASI 100 at Weeks 16 and 52 (ITT, NRI)

B) Week 52

aIn each treatment group, one patient with IGA=2 was mistakenly enrolled and is not shown here.

A) Week 16 B) Week 52

aIn each treatment group, one patient with IGA=2 was mistakenly enrolled and is not shown here.

Disease characteristics

• Duration (<median, ≥median)

• Severity (PASI<20, PASI≥20; IGA=3, IGA=4)

Prior treatment exposure

• Prior biologic exposure (yes, no)

• Prior anti-TNF exposure (yes, no)

• Prior anti-IL-17 exposure (yes, no)

Patient demographics

• Age (<40, 40–<65, ≥65 years)

• Weight (≤100, >100 kg)

Bimekizumab Ustekinumab Bimekizumab 81.9%
Ustekinumab 55.8%

Age (years)

≥65
Baseline weight (kg)

40–<65
<40

≤100
>100

Psoriasis disease duration
<median [14.54 years]
≥median [14.54 years]

Baseline disease severity
PASI <20
PASI ≥20

Baseline IGAa
3
4

Prior biologic exposure
Yes
No

Prior anti-TNF exposure
Yes
No

Prior anti-IL-17 exposure
Yes
No

% of patients
80604020 1000

Ustekinumab
n/N

37/57

79/139
12/24

59/100
32/63

33/66
58/96

34/60
57/102

46/90
45/73

23/41
68/122

45/88
9/18

21/38
70/125

%
64.9%

56.8%
50.0%

59.0%
50.8%

50.0%
60.4%

56.7%
55.9%

51.1%
61.6%

56.1%
55.7%

51.1%
50.0%

55.3%
56.0%

Bimekizumab
n/N

98/123

223/270
39/51

155/196
107/125

95/119
166/201

126/151
136/170

130/152
132/169

78/95
184/226

134/164
30/34

66/76
196/245

%
79.7%

82.6%
76.5%

79.1%
85.6%

79.8%
82.6%

83.4%
80.0%

85.5%
78.1%

82.1%
81.4%

81.7%
88.2%

86.8%
80.0%

10 30 50 70 90

Bimekizumab 58.6%

Ustekinumab 20.9%

Age (years)

≥65
Baseline weight (kg)

40–<65
<40

≤100
>100

Psoriasis disease duration
<median [14.54 years]
≥median [14.54 years]

Baseline disease severity
PASI <20
PASI ≥20

Baseline IGAa
3
4

Prior biologic exposure
Yes
No

Prior anti-TNF exposure
Yes
No

Prior anti-IL-17 exposure
Yes
No

% of patients
80604020 1000

Ustekinumab
n/N

13/57

27/139
7/24

20/100
14/63

12/66
22/96

15/60
19/102

17/90
17/73

6/41
28/122

19/88
2/18

8/38
26/125

%
22.8%

19.4%
29.2%

20.0%
22.2%

18.2%
22.9%

25.0%
18.6%

18.9%
23.3%

14.6%
23.0%

21.6%
11.1%

21.1%
20.8%

Bimekizumab
n/N

77/123

158/270
30/51

112/196
76/125

67/119
120/201

96/151
92/170

82/152
106/169

52/95
136/226

96/164
15/34

45/76
143/245

%
62.6%

58.5%
58.8%

57.1%
60.8%

56.3%
59.7%

63.6%
54.1%

53.9%
62.7%

54.7%
60.2%

58.5%
44.1%

59.2%
58.4%

10 30 50 70 90

Bimekizumab 64.5%

Ustekinumab 38.0%

Age (years)

≥65
Baseline weight (kg)

40–<65
<40

≤100
>100

Psoriasis disease duration
<median [14.54 years]
≥median [14.54 years]

Baseline disease severity
PASI <20
PASI ≥20

Baseline IGAa
3
4

Prior biologic exposure
Yes
No

Prior anti-TNF exposure
Yes
No

Prior anti-IL-17 exposure
Yes
No

% of patients
80604020 1000

Ustekinumab
n/N

29/57

53/139
9/24

37/100
25/63

20/66
42/96

24/60
38/102

28/90
34/73

15/41
47/122

29/88
4/18

17/38
45/125

%
50.9%

38.1%
37.5%

37.0%
39.7%

30.3%
43.8%

40.0%
37.3%

31.1%
46.6%

36.6%
38.5%

33.0%
22.2%

44.7%
36.0%

Bimekizumab
n/N

85/123

177/270
29/51

123/196
83/125

73/119
133/201

98/151
108/170

99/152
107/169

63/95
143/226

103/164
18/34

52/76
154/245

%
69.1%

65.6%
56.9%

62.8%
66.4%

61.3%
66.2%

64.9%
63.5%

65.1%
63.3%

66.3%
63.3%

62.8%
52.9%

68.4%
62.9%

10 30 50 70 90

Age (years)

≥65
Baseline weight (kg)

40–<65
<40

≤100
>100

Psoriasis disease duration
<median [14.54 years]
≥median [14.54 years]

Baseline disease severity
PASI <20
PASI ≥20

Baseline IGAa
3
4

Prior biologic exposure
Yes
No

Prior anti-TNF exposure
Yes
No

Prior anti-IL-17 exposure
Yes
No

% of patients
80604020 1000

Ustekinumab
n/N

34/57

69/139
12/24

54/100
27/63

33/66
48/96

34/60
47/102

43/90
38/73

21/41
60/122

39/88
8/18

15/38
66/125

%
59.6%

49.6%
50.0%

54.0%
42.9%

50.0%
50.0%

56.7%
46.1%

47.8%
52.1%

51.2%
49.2%

44.3%
44.4%

39.5%
52.8%

Bimekizumab
n/N

109/123

230/270
43/51

167/196
106/125

100/119
172/201

138/151
135/170

128/152
145/169

79/95
194/226

139/164
25/34

63/76
210/245

%
88.6%

85.2%
84.3%

85.2%
84.8%

84.0%
85.6%

91.4%
79.4%

84.2%
85.8%

83.2%
85.8%

84.8%
73.5%

82.9%
85.7%

10 30 50 70 90

Bimekizumab 85.0%

Ustekinumab 49.7%

Screening Initial treatment 
period

Maintenance periodScreening

Open-label 
extension study: 

BE BRIGHT 
(NCT03598790) 

20 weeks after 
last dose of IMP: 
safety follow-up

Week 16 Week 24Baseline

2–5 weeks

Bimekizumab 320 mg Q4W

Placebob

Ustekinumab 45/90 mg Q12Wc

Bimekizumab 320 mg Q4W

Week 52

n=321

n=83

n=163

Active comparator period

Patient 
inclusion 
criteria

Moderate to severe disease: 
PASI ≥12, BSA a�ected by 
psoriasis ≥10% and IGA score ≥3 

≥18 years of age

 Plaque psoriasis with ≥6 
months’ symptom duration

N=567
4:1:2

Randomizationa